Clinical importance of antibodies against platelet activating factor in antiphospholipid syndrome manifestations

Tektonidou, MG; Petrovas, CA; Ioannidis, JPA; Vlachoyiannopoulos, PG; Moutsopoulos, HM

dc.contributor.author	Tektonidou, MG	en
dc.contributor.author	Petrovas, CA	en
dc.contributor.author	Ioannidis, JPA	en
dc.contributor.author	Vlachoyiannopoulos, PG	en
dc.contributor.author	Moutsopoulos, HM	en
dc.date.accessioned	2014-03-01T01:49:47Z
dc.date.available	2014-03-01T01:49:47Z
dc.date.issued	2000	en
dc.identifier.issn	0014-2972	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/25922
dc.subject	antiphospholipid syndrome	en
dc.subject	autoantibodies	en
dc.subject	enzyme-linked immunosorbent assay	en
dc.subject	platelet activating factor	en
dc.subject	systemic lupus erythematosus	en
dc.subject	thrombosis	en
dc.subject.classification	Medicine, General & Internal	en
dc.subject.classification	Medicine, Research & Experimental	en
dc.subject.other	SYSTEMIC LUPUS-ERYTHEMATOSUS	en
dc.subject.other	PRELIMINARY CLASSIFICATION CRITERIA	en
dc.subject.other	ANTICARDIOLIPIN ANTIBODIES	en
dc.subject.other	ANTICOAGULANTS	en
dc.subject.other	AUTOANTIBODIES	en
dc.subject.other	PHOSPHOLIPIDS	en
dc.subject.other	PAF	en
dc.title	Clinical importance of antibodies against platelet activating factor in antiphospholipid syndrome manifestations	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	2000	en
heal.abstract	Background We assessed whether antibodies against platelet activating factor (PAF) are related to the presence of antiphospholipid syndrome (APS) clinical manifestations, in particular thrombosis, in patients with connective tissue diseases. Materials and methods Anti-PAF, anticardiolipin (aCL), anti beta 2 glycoprotein I (anti beta 2GPI) and antiphosphatidylcholine (anti-PC) antibodies were determined in 52 patients with APS, 29 patients with systemic lupus erythematosus (SLE) aCL but without APS, 30 patients with SLE without aCL, and 30 patients with scleroderma. A new enzyme-linked immunosorbent assay (ELISA) was developed for determining anti-PAF antibodies in a bovine serum-free fashion. Results The ELISA showed high specificity. Homologous inhibition experiments showed 60-70% inhibition. Anti-PAF antibodies were found in 18/52 APS patients, 10/29 SLE/aCL(+) patients, 9/30 SLE/aCL(-) patients and 3/30 scleroderma patients. Anti-PAF antibodies were significantly associated with anti-PC antibodies (odds ratio [OR] 12.7, P < 0.01), and there was a modest association with immunoglobulin G (IgG) aCL (OR 3.1, P > 0.10), but not with IgM aCL or anti beta 2GPI. Three SLE/aCL(+) patients and five SLE/aCL(-) patients had clinical manifestations characteristic of APS. All these patients had anti-PAF antibodies, while none had high titres of aCL or anti beta 2GPI antibodies and only one had anti-PC antibodies. Among the combined APS and SLE groups, the presence of anti-PAF antibodies was significantly associated with clinical manifestations which are characteristic of APS (OR 2.6, P = 0.02). The effect was independent of IgG aCL and anti beta 2GPI antibodies. Conclusions Anti-PAF antibodies are common in APS and SLE and comprise an independent factor for the development of thrombosis. Several patients experiencing thromboses have anti-PAF antibodies without other antiphospholipid specificities.	en
heal.publisher	BLACKWELL SCIENCE LTD	en
heal.journalName	EUROPEAN JOURNAL OF CLINICAL INVESTIGATION	en
dc.identifier.isi	ISI:000088005000013	en
dc.identifier.volume	30	en
dc.identifier.issue	7	en
dc.identifier.spage	646	en
dc.identifier.epage	652	en